Investments, Funding & Disinvestment

Eli Lilly will obtain exclusive global rights to advance these programmed recombinases through preclinical studies, clinical development, and eventual commercialization.

The investment will enhance AstraZeneca’s existing manufacturing sites in Wuxi, Beijing, Qingdao, and Taizhou, which already serve patients in China and across 70 international markets.

The new facility promises to revolutionize medical care for residents of Pleebo City and the surrounding communities, who have long endured the burden of traveling significant distances to access surgical services.

The AI-powered system automatically analyzes computed tomography (CT) scans that were originally performed for unrelated medical reasons, identifying osteoporotic pathological signs without requiring additional examinations.

The company will showcase its technology on the ABHI UK Pavilion alongside a robust delegation of UK life sciences and health technology companies.

The strategic focus will center on three key areas: enhancing the product portfolio, accelerating digital transformation and e-commerce capabilities, and driving expansion into regional markets across the Middle East and Africa.

Through this acquisition, Mirum gains worldwide rights to brelovitug, a monoclonal antibody that has advanced to Phase III clinical development.

The award acknowledges Sanofi’s consistent efforts in creating sustainable employment opportunities for Saudi nationals while simultaneously building robust leadership capabilities across its regional operations.

The conference attracted regulators, manufacturers, healthcare providers, and industry stakeholders who gathered to examine priorities shaping modern healthcare delivery.

The partnership between these companies stems from a late 2024 licensing agreement in which Corxel obtained worldwide rights to CX11, excluding China, from Vincentage.